Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Prevail Therapeutics stock

Learn how to easily invest in Prevail Therapeutics stock.

Prevail Therapeutics Inc is a biotechnology business based in the US. Prevail Therapeutics shares (PRVL) are listed on the NASDAQ and all prices are listed in US Dollars. Prevail Therapeutics employs 66 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Prevail Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRVL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Prevail Therapeutics stock price (NASDAQ: PRVL)

Use our graph to track the performance of PRVL stocks over time.

Prevail Therapeutics shares at a glance

Information last updated 2021-03-21.
52-week range$9.21 - $23.35
50-day moving average $23.03
200-day moving average $13.95
Wall St. target price$23.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.80

Buy Prevail Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Prevail Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prevail Therapeutics financials

Gross profit TTM $0
Return on assets TTM -29.11%
Return on equity TTM -52.34%
Profit margin 0%
Book value $5.34
Market capitalisation $787.7 million

TTM: trailing 12 months

Shorting Prevail Therapeutics shares

There are currently 1.0 million Prevail Therapeutics shares held short by investors – that's known as Prevail Therapeutics's "short interest". This figure is 7.8% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Prevail Therapeutics shares can be evaluated.

Prevail Therapeutics's "short interest ratio" (SIR)

Prevail Therapeutics's "short interest ratio" (SIR) is the quantity of Prevail Therapeutics shares currently shorted divided by the average quantity of Prevail Therapeutics shares traded daily (recently around 779390.76923077). Prevail Therapeutics's SIR currently stands at 1.3. In other words for every 100,000 Prevail Therapeutics shares traded daily on the market, roughly 1300 shares are currently held short.

However Prevail Therapeutics's short interest can also be evaluated against the total number of Prevail Therapeutics shares, or, against the total number of tradable Prevail Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prevail Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Prevail Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0615% of the tradable shares (for every 100,000 tradable Prevail Therapeutics shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prevail Therapeutics.

Find out more about how you can short Prevail Therapeutics stock.

Prevail Therapeutics share dividends

We're not expecting Prevail Therapeutics to pay a dividend over the next 12 months.

Prevail Therapeutics overview

Prevail Therapeutics Inc. , a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. .

Prevail Therapeutics in the news

There are no recent company news

Frequently asked questions

What percentage of Prevail Therapeutics is owned by insiders or institutions?
Currently 13.001% of Prevail Therapeutics shares are held by insiders and 92.416% by institutions.
How many people work for Prevail Therapeutics?
Latest data suggests 66 work at Prevail Therapeutics.
When does the fiscal year end for Prevail Therapeutics?
Prevail Therapeutics's fiscal year ends in December.
Where is Prevail Therapeutics based?
Prevail Therapeutics's address is: 430 East 29th Street, New York, NY, United States, 10016
What is Prevail Therapeutics's ISIN number?
Prevail Therapeutics's international securities identification number is: US74140Y1010
What is Prevail Therapeutics's CUSIP number?
Prevail Therapeutics's Committee on Uniform Securities Identification Procedures number is: 235691102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site